Ligand Pharmaceuticals Inc
LGNZZ- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000886163
In the last 90 days, Ligand Pharmaceuticals Inc insiders filed 0 open-market purchases and 6 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $16.1M in total
- 6
- 13F holdersQ2 2026
- 0
- 13F valueReported value at the end of Q2 2026
- $0
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding LGNZZ, Q2 2026
No superinvestor reported holding LGNZZ at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Ligand Pharmaceuticals Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 14, 2026 (view filing)4:59 PM ET | Sep 10 | 4 days | Zimmermann MartineDirector | SSale | −1.20K | $285.00 | −$342.0K | −23.5%3.90K after | |
| Sep 8, 2026 (view filing)6:34 PM ET | Sep 3 | 5 days | Reardon AndrewCLO & Secretary | SSale | −5.00K | $286.09 | −$1.43M | −12.0%36.5K after | 5 lots10b5-1 |
| Aug 14, 2026 (view filing)5:05 PM ET | Aug 12 | 2 days | Espinoza OctavioChief Financial Officer | SSale | −31.6K | $292.07 | −$9.24M | −53.3%27.7K after | 10b5-1 |
| Aug 14, 2026 (view filing)5:04 PM ET | Aug 12 | 2 days | Haas JasonDirector | SSale | −7.14K | $292.81 | −$2.09M | −64.2%3.98K after | |
| Aug 4, 2026 (view filing)6:42 PM ET | Aug 3 | 1 day | Reardon AndrewCLO & Secretary | SSale | −5.00K | $288.99 | −$1.44M | −10.7%41.5K after | 10 lots10b5-1 |
| Jul 6, 2026 (view filing)5:11 PM ET | Jul 1 | 5 days | Reardon AndrewCLO & Secretary | SSale | −5.00K | $313.28 | −$1.57M | −10.7%41.5K after | 8 lots10b5-1 |
| Jun 18, 2026 (view filing) | Jun 16 | 2 days | Sabba Stephen LDirector | SSale | −2.15K | $254.00 | −$544.8K | −6.0%33.6K after | |
| Jun 15, 2026 (view filing) | Jun 12 | 3 days | Haas JasonDirector | SSale | −6.46K | $255.58 | −$1.65M | −56.5%4.98K after | 2 lots |
| Jun 12, 2026 (view filing) | Jun 10-11 | 2 days | Aryeh JasonDirector | SSale | −5.00K | $250.00 | −$1.25M | −4.6%102.6K after | 2 lots |
| Jun 12, 2026 (view filing) | Jun 10 | 2 days | Lamattina John LDirector | SSale | −4.59K | $250.88 | −$1.15M | −14.5%27.0K after | 4 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Ligand Pharmaceuticals Inc at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding LGNZZ in 13F filings for Q2 2026.